LONDON (ShareCast) - Balfour Beatty, which describes itself as a world-class engineering, construction, services and investment group, has suffered from association with the construction sector.
But 50% of its business is in public sector work such as transport, education and health, which provide long-term, predictable revenue streams. Buy, says the Mail on Sunday.
One of only two listed pawnbrokers in the UK, H&T shares have fallen from 250p to 179p, largely reflecting market disenchantment with smaller companies. Brokers believe the price should be nearer 260p. Buy, says the Mail on Sunday.
Britain’s biggest publicly traded venture capital group, 3i, delivered a solid pre-close update last week, noting that its strong first quarter had been supported by a robust second quarter. The Telegraph’s Questor last told investors to buy the shares when they were 996p. Trading at a 25 per cent discount to forecast net asset value, they are too cheap to sell at this price. Hold says, Questor.
Silence Therapeutics operates in a field of biotech drug development called RNA interference, which opens possibilities for lots of new medicines. Silence said this week that it was confident of signing new biotech and pharmaceutical collaborations in the next few months. Clearly, there is scope for a substantial uplift in Silence’s valuation. Buy, says Questor.
Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.
0.000p ()
